Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
| ▸ | DUT | P33316 | 5/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034517 | 1.00 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034520 | 0.89 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034522 | 0.88 | POLB (0.42) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26034516 | 0.82 | CRBN (0.37) | TSHRDUT | |
| SCHEMBL24205049 | 0.81 | DUT (0.50) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205058 | 0.81 | DUT (0.50) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205059 | 0.81 | DUT (0.50) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205328 | 0.81 | DUT (0.50) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL26035091 | 0.81 | DUT (0.50) | TSHRPOLBAPEX1HTTTDP1 | |
| SCHEMBL24205191 | 0.81 | TSHR (0.43) | TSHRPOLBAPEX1HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2022012798-A1 | OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2022-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273455-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | TSHR 4592/4885POLB 1376/4885APEX1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.